Brokerages Set Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Target Price at $10.91
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the firm. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $10.91.
TTPH has been the topic of several research analyst reports. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Monday, June 20th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Wednesday, July 6th.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 3.67 on Wednesday. Tetraphase Pharmaceuticals has a one year low of $3.12 and a one year high of $12.45. The stock’s market capitalization is $134.68 million. The stock has a 50 day moving average price of $3.83 and a 200 day moving average price of $4.27.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. Tetraphase Pharmaceuticals had a negative return on equity of 35.43% and a negative net margin of 821.25%. The firm earned $1.20 million during the quarter, compared to analyst estimates of $2.05 million. During the same quarter in the previous year, the firm posted ($0.72) earnings per share. The company’s quarterly revenue was down 63.6% on a year-over-year basis. Equities analysts forecast that Tetraphase Pharmaceuticals will post ($1.98) earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Pacad Investment Ltd. boosted its position in shares of Tetraphase Pharmaceuticals by 144.5% in the first quarter. Pacad Investment Ltd. now owns 62,443 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 36,900 shares in the last quarter. Teton Advisors Inc. bought a new position in shares of Tetraphase Pharmaceuticals during the second quarter valued at $103,000. Acadian Asset Management LLC bought a new position in shares of Tetraphase Pharmaceuticals during the second quarter valued at $257,000. Geode Capital Management LLC boosted its position in shares of Tetraphase Pharmaceuticals by 0.7% in the first quarter. Geode Capital Management LLC now owns 233,255 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 1,713 shares in the last quarter. Finally, Gabelli Funds LLC boosted its position in shares of Tetraphase Pharmaceuticals by 103.4% in the second quarter. Gabelli Funds LLC now owns 120,000 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 61,000 shares in the last quarter. Institutional investors and hedge funds own 59.41% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.
Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.